Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

@article{Machiels2010PhaseIS,
  title={Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.},
  author={Jean-Pascal Machiels and Stephanie L Henry and Sylvie Zanetta and M C Kaminsky and Nicolas Michoux and Denis Rommel and Sandra Schmitz and Emmanuelle Bompas and A F Dillies and Sandrine J. Faivre and Anne Moxhon and Thierry Duprez and Joel Guigay},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 1},
  pages={21-8}
}
PURPOSE To assess the efficacy and toxicity of sunitinib monotherapy in palliative squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS Thirty-eight patients with SCCHN having evidence of progressive disease (PD) were treated with sunitinib 37.5 mg/d given continuously until PD or unacceptable toxicity. The primary end point was the rate of disease control, defined as stable disease (SD) or partial response (PR) at 6 to 8 weeks after treatment initiation (two-stage design… CONTINUE READING